CSCR
MCID: CNT060
MIFTS: 38

Central Serous Chorioretinopathy (CSCR)

Categories: Bone diseases, Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 52 58 71
Central Serous Chorioretinopathy After Bone Marrow Transplantation 52
Central Serous Choroidopathy 52
Cscr 58

Characteristics:

Orphanet epidemiological data:

58
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

ICD10 via Orphanet 33 H35.7
UMLS via Orphanet 72 C0730328
Orphanet 58 ORPHA443079
UMLS 71 C0730328

Summaries for Central Serous Chorioretinopathy

NIH Rare Diseases : 52 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina , the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor . Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and kuhnt-junius degeneration. An important gene associated with Central Serous Chorioretinopathy is CFH (Complement Factor H), and among its related pathways/superpathways are Complement and coagulation cascades and Cell adhesion_ECM remodeling. The drugs Bevacizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone marrow.

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 251, show less)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.2 CFH ARMS2
2 kuhnt-junius degeneration 30.8 CFH ARMS2
3 multifocal choroiditis 30.7 CFH ARMS2
4 macular degeneration, age-related, 1 30.7 CFH C4B ARMS2
5 angioid streaks 30.4 CFH ARMS2
6 antiphospholipid syndrome 30.0 SERPINE1 PLAT CFH
7 chronic kidney disease 29.3 SERPINE1 NR3C2 CFH
8 bestrophinopathy, autosomal recessive 11.8
9 retinal detachment 11.2
10 microvascular complications of diabetes 5 10.8
11 scotoma 10.7
12 macular retinal edema 10.7
13 sleep apnea 10.6
14 periodontal ehlers-danlos syndrome 10.6
15 uveitis 10.6
16 retinal disease 10.6
17 helicobacter pylori infection 10.5
18 vogt-koyanagi-harada disease 10.5
19 refractive error 10.5
20 eye disease 10.5
21 retinal vascular disease 10.5
22 retinal degeneration 10.5
23 yemenite deaf-blind hypopigmentation syndrome 10.4
24 joint laxity, short stature, and myopia 10.4
25 neuroretinitis 10.4
26 myopia 10.4
27 conn's syndrome 10.4
28 neuritis 10.4
29 retinitis 10.4
30 coronary heart disease 1 10.4
31 impotence 10.4
32 ulcerative colitis 10.4
33 optic nerve disease 10.3
34 hemangioma 10.3
35 sleep disorder 10.3
36 peptic ulcer disease 10.3
37 cataract 10.3
38 lupus erythematosus 10.3
39 47,xyy 10.3
40 multiple sclerosis 10.3
41 melanoma, cutaneous malignant 10 10.3
42 colitis 10.3
43 optic neuritis 10.3
44 posterior uveitis 10.3
45 telangiectasis 10.3
46 color blindness 10.3
47 acute retrobulbar neuritis 10.3
48 retinal vein occlusion 10.3
49 melanoma 10.3
50 adenoma 10.3
51 neuropathy 10.3
52 pik3ca-related overgrowth syndrome 10.3
53 catastrophic antiphospholipid syndrome 10.3 SERPINE1 CFH
54 fibrinolytic defect 10.2 SERPINE1 PLAT
55 plasminogen activator inhibitor-1 deficiency 10.2 SERPINE1 PLAT
56 argentine hemorrhagic fever 10.2 SERPINE1 PLAT
57 carotid artery thrombosis 10.2 SERPINE1 PLAT
58 bullous retinoschisis 10.2 CFH ARMS2
59 post-thrombotic syndrome 10.2 SERPINE1 PLAT
60 basal laminar drusen 10.2 CFH ARMS2
61 neurofibromatosis, type ii 10.2
62 autoimmune disease 10.2
63 gastroesophageal reflux 10.2
64 systemic lupus erythematosus 10.2
65 pituitary adenoma 4, acth-secreting 10.2
66 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
67 myasthenia gravis 10.2
68 nonarteritic anterior ischemic optic neuropathy 10.2
69 retinitis pigmentosa 10.2
70 intraocular pressure quantitative trait locus 10.2
71 graft-versus-host disease 10.2
72 leukemia, acute lymphoblastic 3 10.2
73 exanthem 10.2
74 adrenal cortical adenoma 10.2
75 keratoconus 10.2
76 retinal vasculitis 10.2
77 scleritis 10.2
78 adult-onset still's disease 10.2
79 hypothyroidism 10.2
80 purpura 10.2
81 systemic scleroderma 10.2
82 pustulosis of palm and sole 10.2
83 rhinitis 10.2
84 acth-secreting pituitary adenoma 10.2
85 macular holes 10.2
86 vasculitis 10.2
87 psoriasis 10.2
88 diabetic macular edema 10.2
89 ocular hypertension 10.2
90 meibomian cyst 10.2
91 48,xyyy 10.2
92 back pain 10.2
93 thrombotic microangiopathy 10.2
94 retinal drusen 10.2 CFH ARMS2
95 thrombophilia due to activated protein c resistance 10.2 SERPINE1 PLAT
96 thrombophlebitis 10.2 SERPINE1 PLAT
97 coronary thrombosis 10.2 SERPINE1 PLAT
98 doyne honeycomb retinal dystrophy 10.2 CFH ARMS2
99 chronic venous insufficiency 10.2 SERPINE1 PLAT
100 histoplasmosis 10.2 CFH ARMS2
101 venous insufficiency 10.2 SERPINE1 PLAT
102 louse-borne relapsing fever 10.2 CFH C4B
103 relapsing fever 10.2 CFH C4B
104 pulmonary artery disease 10.2 SERPINE1 PLAT
105 portal vein thrombosis 10.1 SERPINE1 PLAT
106 hepatic veno-occlusive disease 10.1 SERPINE1 PLAT
107 meningococcal meningitis 10.1 CFH C4B
108 thrombotic thrombocytopenic purpura 10.1 PLAT CFH
109 thrombophilia due to thrombin defect 10.1 SERPINE1 PLAT
110 severe pre-eclampsia 10.1 SERPINE1 CFH
111 vein disease 10.1 SERPINE1 PLAT
112 complement deficiency 10.1 CFH C4B
113 hallermann-streiff syndrome 10.1
114 hypotrichosis 10.1
115 vitreous detachment 10.1
116 dwarfism 10.1
117 degeneration of macula and posterior pole 10.1 CFH ARMS2
118 limb ischemia 10.1 SERPINE1 PLAT
119 anisocoria 10.0
120 spondyloarthropathy 1 10.0
121 apnea, obstructive sleep 10.0
122 exudative vitreoretinopathy 1 10.0
123 fibrosis of extraocular muscles, congenital, 1 10.0
124 glaucoma, primary open angle 10.0
125 hashimoto thyroiditis 10.0
126 attention deficit-hyperactivity disorder 10.0
127 marfan syndrome 10.0
128 migraine with or without aura 1 10.0
129 pemphigus vulgaris, familial 10.0
130 pulmonary hypertension, primary, 1 10.0
131 strabismus 10.0
132 sturge-weber syndrome 10.0
133 temporal arteritis 10.0
134 thrombocytopenic purpura, autoimmune 10.0
135 lymphoma, hodgkin, classic 10.0
136 myeloma, multiple 10.0
137 retinoschisis 1, x-linked, juvenile 10.0
138 glaucoma-related pigment dispersion syndrome 10.0
139 patent ductus venosus 10.0
140 astigmatism 10.0
141 lymphoma, non-hodgkin, familial 10.0
142 birdshot chorioretinopathy 10.0
143 body mass index quantitative trait locus 1 10.0
144 allergic rhinitis 10.0
145 hypereosinophilic syndrome, idiopathic 10.0
146 anxiety 10.0
147 pulmonary hypertension 10.0
148 aniseikonia 10.0
149 inflammatory bowel disease 10.0
150 vitelliform macular dystrophy 10.0
151 androgenic alopecia 10.0
152 arteritic anterior ischemic optic neuropathy 10.0
153 sexual disorder 10.0
154 alexithymia 10.0
155 thrombosis 10.0
156 cytomegalovirus retinitis 10.0
157 isolated ectopia lentis 10.0
158 cysticercosis 10.0
159 pre-eclampsia 10.0
160 microphthalmia 10.0
161 open-angle glaucoma 10.0
162 chorioretinal scar 10.0
163 prostatic hypertrophy 10.0
164 solar retinopathy 10.0
165 gnathomiasis 10.0
166 heart disease 10.0
167 hypertensive retinopathy 10.0
168 polycystic ovary syndrome 10.0
169 sympathetic ophthalmia 10.0
170 inflammatory spondylopathy 10.0
171 peripheral retinal degeneration 10.0
172 retinal ischemia 10.0
173 diarrhea 10.0
174 eclampsia 10.0
175 posterior scleritis 10.0
176 premature ejaculation 10.0
177 acute closed-angle glaucoma 10.0
178 achromatopsia 10.0
179 facial paralysis 10.0
180 iritis 10.0
181 oral candidiasis 10.0
182 candidiasis 10.0
183 personality disorder 10.0
184 angioedema 10.0
185 vascular disease 10.0
186 relapsing polychondritis 10.0
187 skin atrophy 10.0
188 narcissistic personality disorder 10.0
189 glomerulonephritis 10.0
190 pulmonary tuberculosis 10.0
191 pituitary adenoma 10.0
192 syphilis 10.0
193 prostate disease 10.0
194 adjustment disorder 10.0
195 kidney disease 10.0
196 congestive heart failure 10.0
197 bronchitis 10.0
198 thyroid hyalinizing trabecular adenoma 10.0
199 fibromyalgia 10.0
200 spondylitis 10.0
201 thyroiditis 10.0
202 anthrax disease 10.0
203 diverticulitis 10.0
204 end stage renal disease 10.0
205 crohn's disease 10.0
206 rubella 10.0
207 chorioretinitis 10.0
208 narcolepsy 10.0
209 pemphigus 10.0
210 mechanical strabismus 10.0
211 pathologic nystagmus 10.0
212 senile cataract 10.0
213 alopecia 10.0
214 hypereosinophilic syndrome 10.0
215 heritable pulmonary arterial hypertension 10.0
216 congenital rubella 10.0
217 cytokine deficiency 10.0
218 eales disease 10.0
219 gnathostoma infection 10.0
220 homologous wasting disease 10.0
221 linear scleroderma 10.0
222 macular telangiectasia type 2 10.0
223 punctate inner choroidopathy 10.0
224 secondary adrenal insufficiency 10.0
225 susac syndrome 10.0
226 weber syndrome 10.0
227 farsightedness 10.0
228 hypertonia 10.0
229 pouchitis 10.0
230 acute sensory ataxic neuropathy 10.0
231 chronic relapsing inflammatory optic neuropathy 10.0
232 optic disc pit 10.0
233 acth-dependent cushing syndrome 10.0
234 hemorrhagic disease 10.0 SERPINE1 PLAT
235 hellp syndrome 10.0 SERPINE1 PLAT CFH
236 hereditary angioedema 9.9 PLAT C4B
237 hemolytic uremic syndrome, atypical 1 9.9 CFH C4B
238 disseminated intravascular coagulation 9.9 SERPINE1 PLAT
239 pneumoconiosis 9.9 SERPINE1 GSTM1
240 afibrinogenemia, congenital 9.8 SERPINE1 PLAT C4B
241 oral cancer 9.8 SLC7A5 GSTM1
242 complement component 2 deficiency 9.8 CFH C4B ARMS2
243 endocarditis 9.8 SERPINE1 PLAT
244 steroid inherited metabolic disorder 9.8 NR3C2 C4B
245 cerebrovascular disease 9.7 SERPINE1 PLAT GSTM1
246 hemolytic-uremic syndrome 9.6 CFH C4B
247 acute myocardial infarction 9.6 SERPINE1 PLAT NR3C2
248 cardiovascular system disease 9.5 SERPINE1 PLAT NR3C2
249 myocardial infarction 9.3 SERPINE1 PLAT NR3C2 CFH
250 body mass index quantitative trait locus 11 9.1 SERPINE1 NR3C2 GSTM1 CFH
251 hypertension, essential 8.8 SERPINE1 PLAT NR3C2 GSTM1

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 126, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Verteporfin Approved, Investigational Phase 4 129497-78-5
3
Ranibizumab Approved Phase 4 347396-82-1 459903
4
Eplerenone Approved Phase 4 107724-20-9 150310 443872
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
7 Mitogens Phase 4
8 Endothelial Growth Factors Phase 4
9 Antineoplastic Agents, Immunological Phase 4
10 Angiogenesis Inhibitors Phase 4
11 Dermatologic Agents Phase 4
12 Photosensitizing Agents Phase 4
13 Hormone Antagonists Phase 4
14 Hormones Phase 4
15 Mineralocorticoids Phase 4
16 Antihypertensive Agents Phase 4
17 Mineralocorticoid Receptor Antagonists Phase 4
18 diuretics Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Anti-Inflammatory Agents Phase 4
21 glucocorticoids Phase 4
22 Triamcinolone diacetate Phase 4
23 triamcinolone acetonide Phase 4
24 Triamcinolone hexacetonide Phase 4
25 Pharmaceutical Solutions Phase 4
26
Brinzolamide Approved Phase 2 138890-62-7 68844
27
leucovorin Approved Phase 2 58-05-9 6006 143
28
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
29
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
30
Zinc Approved, Investigational Phase 2 7440-66-6 32051
31
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
32
Copper Approved, Investigational Phase 2 7440-50-8 27099
33
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
34
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
35
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
36
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
37
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
40
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
41
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
42
Spironolactone Approved Phase 1, Phase 2 52-01-7, 1952-01-7 5833
43
Sodium citrate Approved, Investigational Phase 2 68-04-2
44
Finasteride Approved Phase 2 98319-26-7 57363
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
48
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
49
Lutein Approved, Investigational, Nutraceutical Phase 2 127-40-2 6433159
50
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
51
Manganese Approved, Nutraceutical Phase 2 7439-96-5 27854
52
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
53 Tocotrienol Investigational Phase 2 6829-55-6
54 Anecortave Investigational Phase 1, Phase 2 10184-70-0
55 Carbonic Anhydrase Inhibitors Phase 2
56 Immunologic Factors Phase 2
57 Folic Acid Antagonists Phase 2
58 Vitamin B Complex Phase 2
59 Immunosuppressive Agents Phase 2
60 Folate Phase 2
61 Antimetabolites Phase 2
62 Vitamin B9 Phase 2
63 Vitamins Phase 2
64 retinol Phase 2
65 Antioxidants Phase 2
66 Retinol palmitate Phase 2
67 Copper Supplement Phase 2
68 Protective Agents Phase 2
69 Tocopherols Phase 2
70 Vitamin B2 Phase 2
71 Tocotrienols Phase 2
72 Anti-Infective Agents Phase 1, Phase 2
73 Antacids Phase 1, Phase 2
74 Anti-Ulcer Agents Phase 1, Phase 2
75 Proton Pump Inhibitors Phase 1, Phase 2
76 Antiprotozoal Agents Phase 1, Phase 2
77 Anti-Bacterial Agents Phase 1, Phase 2
78 Antiparasitic Agents Phase 1, Phase 2
79 Cytochrome P-450 Enzyme Inhibitors Phase 2
80 Antifungal Agents Phase 2
81 Cytochrome P-450 CYP3A Inhibitors Phase 2
82 Hydrocortisone 17-butyrate 21-propionate Phase 1, Phase 2
83 Hydrocortisone hemisuccinate Phase 1, Phase 2
84 Contraceptive Agents Phase 2
85 Contraceptives, Oral Phase 2
86 Contraceptives, Postcoital Phase 2
87 interferons Phase 1, Phase 2
88 Antiviral Agents Phase 1, Phase 2
89 Interferon-gamma Phase 1, Phase 2
90 Ophthalmic Solutions Phase 1, Phase 2
91 Citrate Phase 2
92 Phosphodiesterase Inhibitors Phase 2
93 Phosphodiesterase 5 Inhibitors Phase 2
94 Vasodilator Agents Phase 2
95 Sildenafil Citrate Phase 2 171599-83-0
96 5-alpha Reductase Inhibitors Phase 2
97
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
98
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
99
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
100 Gastrointestinal Agents Phase 1
101 Antirheumatic Agents Phase 1
102 Antineoplastic Agents, Hormonal Phase 1
103 Antiemetics Phase 1
104 Analgesics, Non-Narcotic Phase 1
105 Cyclooxygenase 2 Inhibitors Phase 1
106 Analgesics Phase 1
107 Cyclooxygenase Inhibitors Phase 1
108 Anti-Inflammatory Agents, Non-Steroidal Phase 1
109
protease inhibitors Phase 1
110 HIV Protease Inhibitors Phase 1
111 BB 1101 Phase 1
112
Pyrantel Approved, Vet_approved 15686-83-6
113
Phenylephrine Approved 59-42-7 6041
114
Oxymetazoline Approved, Investigational 1491-59-4 4636
115
Tropicamide Approved, Investigational 1508-75-4 5593
116
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
117 Immunoglobulins
118 Antibodies
119 Plasminogen
120 Insulin, Globin Zinc
121 insulin
122 Pyrantel Pamoate
123 Complement Factor H
124 Complement System Proteins
125 Anesthetics
126 Mydriatics

Interventional clinical trials:

(showing 73, show less)
# Name Status NCT ID Phase Drugs
1 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
2 A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy Completed NCT01574430 Phase 4
3 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
4 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial) Active, not recruiting NCT03079141 Phase 4 Eplerenone
7 Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis Active, not recruiting NCT03586687 Phase 4 Triamcinolone
8 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
9 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
10 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
11 A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Completed NCT02735213 Phase 2, Phase 3
12 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
13 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT03542006 Phase 2 Brinzolamide Ophthalmic
14 Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
15 Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
16 Eplerenone for Central Serous Chorioretinopathy: A Pilot Study Completed NCT01822561 Phase 2 Eplerenone 50mg
17 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
18 Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
19 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
20 A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole. Completed NCT00211393 Phase 2 ketoconazole
21 Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
22 Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
23 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC) Completed NCT02354170 Phase 2 Mifepristone;Placebo
24 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
25 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial Completed NCT00987077 Phase 2
26 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
27 Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
28 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
29 Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois Completed NCT01552044 Phase 1, Phase 2 Spironolactone;Placebo
30 Phase 2 Study of Non-damaging Retinal Laser Therapy Using PASCAL Laser With Endpoint Management Software for Macular Diseases Recruiting NCT01975103 Phase 2
31 Sildenafil for Treatment of Choroidal Ischemia Recruiting NCT04356716 Phase 2 Sildenafil
32 Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
33 Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid. Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
34 Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy Completed NCT02036632 Phase 1
35 Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120636 Phase 1 Episcleral Celecoxib
36 Phase I Study of Sequestered Transscleral, Controlled-Release Dexamethasone Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120311 Phase 1 Episcleral Dexamethasone
37 Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab Unknown status NCT00864773
38 Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy Unknown status NCT02815176
39 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863
40 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992
41 Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease Unknown status NCT02443129
42 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884
43 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 25mg Eplerenone;Placebo
44 Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology Completed NCT01610804
45 Persona of Central Serous Chorioretinopathy Completed NCT02819622
46 Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy Completed NCT03497000
47 Treatment of Chronic Recalcitrant or Unresponsive Central Serous Chorioretinopathy Via Electromagnetic Stimulation And Platelet- Rich Plasma Completed NCT04224831
48 Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis Completed NCT01378130
49 Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
50 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Completed NCT01327170
51 Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Completed NCT01434095
52 Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Completed NCT01019668 Verteporfin PDT, half-dose;verteporfin PDT, half-fluence
53 Optical Coherence Tomography Angiography (OCT-A) Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy (CSC) Completed NCT03950089
54 Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Traditional Laser Therapy on Acute Central Serous Chorioretinopathy Completed NCT02784665
55 Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy Completed NCT00802906 bevacizumab
56 Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC). Completed NCT01880788
57 Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Completed NCT01692938
58 A Prospective, Multi-center, Randomized, Double-blinded (Subject & Independent Efficacy Evaluator), Comparative Clinical Study to Evaluate the Efficacy and Safety of SRT (Selective Retina Therapy) With 'R:GEN' in Patients With Central Serous Chorioretinopathy Completed NCT03758963
59 Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Completed NCT03339856
60 Correlation Between Choroidal Thickness and Myopia Using Swept Source OCT Completed NCT03542448
61 Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration Completed NCT01115231
62 The Changes of Retinal and Choroidal Capillaries After Half-dose Photodynamic Therapy Measured by Angio- OCT in Eyes With Central Serous Chorioretinopathy Recruiting NCT03692169
63 Comparison of Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy Recruiting NCT04410861
64 Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients Recruiting NCT02081339 ranibizumab, aflibercept, pegaptanib, verteporphin
65 Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases Recruiting NCT02141308
66 Prospective Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Active, not recruiting NCT02587767
67 Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen (TOLERANT Study) Active, not recruiting NCT02550002 Aflibercept
68 Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization Not yet recruiting NCT04439708
69 Selective Retinal Pigment Epithelium Laser Therapy (SRT) for Macular Disease of the Retina Suspended NCT02088151
70 Multimodal Imaging in Central Serous Chorioretinopathy Terminated NCT02889185
71 A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy Terminated NCT01982383
72 Subfoveal Choroidal Thickness in Thai Population Terminated NCT02551601
73 Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration Withdrawn NCT01256580 Bevacizumab (Avastin; Genentech, Inc.);Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

40
Eye, Retina, Bone Marrow, Bone, Brain, Endothelial, Testes

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(showing 1961, show less)
# Title Authors PMID Year
1
DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 61
31181038 2020
2
Identifying central serous chorioretinopathy biomarkers in coexisting diabetic retinopathy: a multimodal imaging study. 61
31563867 2020
3
FUNDUS AUTOFLUORESCENCE PATTERNS IN CENTRAL SEROUS CHORIORETINOPATHY. 61
31157711 2020
4
Systemic oxidative stress level in patients with central serous chorioretinopathy. 61
32266471 2020
5
USE OF CHOROIDAL VASCULARITY INDEX FOR CHOROIDAL STRUCTURAL EVALUATION IN CENTRAL SEROUS CHORIORETINOPATHY WITH CHOROIDAL NEOVASCULARIZATION. 61
31259812 2020
6
Fluorescein angiography as a primary guide for reduced-fluence photodynamic therapy for the treatment of chronic central serous chorioretinopathy. 61
32274613 2020
7
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. 61
31615761 2020
8
Cerebral Neurovascular Coupling Impairment in Central Serous Chorioretinopathy. 61
32564029 2020
9
Prospective Impact of Sildenafil on Chronic cEntral Serous chorioretinopathy. 61
32525054 2020
10
Microrip of Retinal Pigment Epithelium in Central Serous Chorioretinopathy. 61
32525538 2020
11
Intraocular gnathostomiasis and central serous chorioretinopathy. 61
32506596 2020
12
Purtscher-like retinopathy in adult-onset Still's disease, complicated by treatment-related central serous chorioretinopathy. 61
32140617 2020
13
The Effect of Obstructive Sleep Apnea on Absolute Risk of Central Serous Chorioretinopathy. 61
32574769 2020
14
Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. 61
32503484 2020
15
Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. 61
32279234 2020
16
Choroidal vascular densities of macular disease on ultra-widefield indocyanine green angiography. 61
32494872 2020
17
Hair cortisol concentrations in chronic central serous chorioretinopathy. 61
31608607 2020
18
Central serous chorioretinopathy: risk factors for serous retinal detachment in fellow eyes. 61
31473627 2020
19
Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. 61
32532761 2020
20
Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. 61
32170365 2020
21
COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. 61
30897068 2020
22
Study of vessel density by optical coherence tomography angiography in patients with central serous chorioretinopathy after low-fluence photodynamic therapy. 61
32198017 2020
23
Quantitative analyses of diameter and running pattern of choroidal vessels in central serous chorioretinopathy by en face images. 61
32533066 2020
24
Relationship between photoreceptor layer changes before half-dose photodynamic therapy and functional and anatomic outcomes in central serous chorioretinopathy. 61
32546748 2020
25
Changes in choroidal blood flow velocity in patients diagnosed with central serous chorioretinopathy during follow-up for pachychoroid pigment epitheliopathy. 61
32215340 2020
26
Retinal structural changes in patients receiving tamoxifen therapy by spectral-domain optical coherence tomography. 61
32100607 2020
27
Novel insights into retinal neovascularization secondary to central serous chorioretinopathy using 3D optical coherence tomography angiography. 61
32123772 2020
28
Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. 61
32575806 2020
29
Central serous chorioretinopathy secondary to subtenon triamcinolone injection: A new hypothesis for the mechanism. 61
32496660 2020
30
[Indications for fluorescein angiography and optical coherence tomography angiography (OCTA) in medical retina: Changes from 2015 and 2018]. 61
32115267 2020
31
Outer retinal tubulations in central serous chorioretinopathy associated with choroidal neovascularisation. 61
32370611 2020
32
Hypoproteinemia as a parameter of poor perinatal/neonatal outcomes in women with preeclampsia diagnosed as hypertension plus proteinuria. 61
32492636 2020
33
Central serous chorioretinopathy and achromatopsia: a case report. 61
32424630 2020
34
Multicolour imaging in central serous chorioretinopathy. 61
31489701 2020
35
Oral medications for central serous chorioretinopathy: a literature review. 61
31527760 2020
36
PHOTORECEPTOR OUTER SEGMENT IS EXPANDED IN THE FELLOW EYE OF PATIENTS WITH UNILATERAL CENTRAL SEROUS CHORIORETINOPATHY. 61
32404847 2020
37
Commentary: Our understanding of central serous chorioretinopathy-coming a full circle? 61
32317462 2020
38
Commentary: Multicolor imaging: A new imaging tool in central serous chorioretinopathy. 61
32317465 2020
39
Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. 61
32112141 2020
40
Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. 61
32407978 2020
41
Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy. 61
32317461 2020
42
Validation of multicolor imaging signatures of central serous chorioretinopathy lesions vis-a-vis conventional color fundus photographs. 61
32317464 2020
43
A comparative study of the choroidal vascularity indexes in the fellow eyes of patients with pachychoroid neovasculopathy and central serous chorioretinopathy by binarization method. 61
32415536 2020
44
CLINICAL APPLICATION OF MULTICOLOR IMAGING IN CENTRAL SEROUS CHORIORETINOPATHY. 61
30608348 2020
45
Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy. 61
31268769 2020
46
THE INCIDENCE OF NEOVASCULARIZATION IN CENTRAL SEROUS CHORIORETINOPATHY BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 61
32310626 2020
47
A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakage. 61
32264706 2020
48
Pachychoroid disease: a new perspective on exudative maculopathy. 61
32318919 2020
49
Optical coherence tomography angiography in primary eye care. 61
32285493 2020
50
Scleral thinning surgery for bullous retinal detachment with retinal pigment epithelial tear in central serous chorioretinopathy: a case report. 61
32252699 2020
51
Swept-source optical coherence tomography angiography alleviates shadowing artifacts caused by subretinal fluid. 61
32333339 2020
52
REVISED CLASSIFICATION OF THE OPTICAL COHERENCE TOMOGRAPHY OUTER RETINAL BANDS BASED ON CENTRAL SEROUS CHORIORETINOPATHY ANALYSIS. 61
32271277 2020
53
Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. 61
32000971 2020
54
Reply to Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. 61
32007226 2020
55
CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
32251241 2020
56
Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy. 61
31925659 2020
57
Cross-over to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy. 61
32289294 2020
58
Diurnal trajectories of salivary cortisol and α-amylase and psychological profiles in patients with central serous chorioretinopathy. 61
31842621 2020
59
Response to comment on: Flat irregular pigment epithelium detachment in central serous chorioretinopathy: A correlation with choroidal neovascular membrane. 61
32174607 2020
60
Comparison of the outcomes of photodynamic therapy for central serous chorioretinopathy with or without subfoveal fibrin. 61
32291401 2020
61
Choroidal anatomical alterations following photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study. 61
32360342 2020
62
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY. 61
32343102 2020
63
Photoreceptor assessment in focal laser-treated central serous chorioretinopathy using adaptive optics and fundus autofluorescence. 61
32282703 2020
64
Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy. 61
32265200 2020
65
Comment on: Flat irregular pigment epithelium detachment in central serous chorioretinopathy: Correlation with choroidal neovascular membrane. 61
32174606 2020
66
ELONGATED PHOTORECEPTOR OUTER SEGMENT LENGTH AND PROGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
30640283 2020
67
Solar retinal phototoxicity masquerading as self-inflicted handheld laser-induced lesions. 61
31909293 2020
68
Bilateral and multifocal central serous chorioretinopathy after injecting triamcinolone into a chalazion. 61
32001028 2020
69
The significance of pigment epithelial detachment in central serous chorioretinopathy. 61
32122162 2020
70
Comparison of Half-Time and Half-Irradiance Photodynamic Therapy in Nonresolving Central Serous Chorioretinopathy. 61
31825265 2020
71
Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy. 61
32143668 2020
72
Choriocapillary vascular density in central serous chorioretinopathy complicated by choroidal neovascularization. 61
31747634 2020
73
Chronic Neovascular Central Serous Chorioretinopathy: A Stress/Rest Optical Coherence Tomography Angiography Study. 61
31715159 2020
74
Choroidal thickness estimation from colour fundus photographs by adaptive binarisation and deep learning, according to central serous chorioretinopathy status. 61
32221317 2020
75
QUANTIFICATION OF CHOROIDAL VASCULATURE BY HIGH-QUALITY STRUCTURE EN FACE SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY IMAGES IN EYES WITH CENTRAL SEROUS CHORIORETINOPATHY. 61
30550530 2020
76
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography. 61
32235227 2020
77
Bioadsorbents from algae residues for heavy metal ions adsorption: chemical modification, adsorption behaviour and mechanism. 61
31996100 2020
78
En-face choroidal vascularity in central serous chorioretinopathy. 61
32103680 2020
79
Nanoencapsulation of synergistic antioxidant fruit and vegetable concentrates and their stability during in vitro digestion. 61
31650546 2020
80
Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. 61
32051140 2020
81
Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. 61
31079056 2020
82
Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. 61
32042181 2020
83
Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography. 61
31724090 2020
84
Corticosteroids usage and central serous chorioretinopathy: a meta-analysis. 61
31734720 2020
85
Abnormal retrobulbar blood flow variables in central serous chorioretinopathy. 61
31943277 2020
86
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. 61
31982075 2020
87
Subretinal hyperreflective material in central serous chorioretinopathy. 61
31856489 2020
88
Response to comments on: Clinical profile of uveitis patients developing central serous chorioretinopathy - An experience at a tertiary eye care center in India. 61
31856557 2020
89
Severe proteinuria as a parameter of worse perinatal/neonatal outcomes in women with preeclampsia. 61
31972468 2020
90
OCTA characterisation of microvascular retinal alterations in patients with central serous chorioretinopathy. 61
31949095 2020
91
Curcumin-Based Treatment for Macular Edema from Uncommon Etiologies: Efficacy and Safety Assessment. 61
31913752 2020
92
A rare case of diabetic macular edema with a central serous chorioretinopathy presenting as pseudohypopyon over macula. 61
31856512 2020
93
Multimodal Imaging in Fibrinous Central Serous Chorioretinopathy Compared with Exudative Maculopathy. 61
32008002 2020
94
Association of Irregular Pigment Epithelial Detachment in Central Serous Chorioretinopathy with Genetic Variants Implicated in Age-related Macular Degeneration. 61
31988359 2020
95
Comparison of OCT and OCTA manifestations among untreated PCV, neovascular AMD, and CSC in Chinese population. 61
31956576 2020
96
Eplerenone is not superior to placebo for chronic central serous chorioretinopathy. 61
31982052 2020
97
Relapsing Pigment Epithelial Detachment in Central Serous Chorioretinopathy After Dilated Eye Examination. 61
31999295 2020
98
Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy. 61
32148947 2020
99
Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort. 61
31856486 2020
100
Commentary: Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort. 61
31856488 2020
101
Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy: OCT Angiography Findings and Risk Factors. 61
32089870 2020
102
Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy. 61
32425502 2020
103
Increased Risk of Central Serous Chorioretinopathy among Patients with Nonorganic Sleep Disturbance. 61
32104592 2020
104
Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats. 61
31751144 2020
105
Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy. 61
31929582 2020
106
Correlation of retinal changes with choroidal changes in acute and recurrent central serous chorioretinopathy assessed by swept-source optical coherence tomography. 61
32010882 2020
107
Comparison of 532 nm Micropulse Green Laser versus Continuous-Wave 532 nm Green Laser in Chronic Central Serous Chorioretinopathy: Long-Term Follow-Up. 61
32089869 2020
108
MULTIPLE SEROUS PIGMENT EPITHELIAL DETACHMENTS IN ASSOCIATION WITH MAJOR WEIGHT LOSS: CASE REPORT AND REVIEW OF THE LITERATURE. 61
28834921 2020
109
Efficacy of nanosecond laser treatment in central serous chorioretinopathy with and without atrophy of retinal pigment epithelium. 61
32518690 2020
110
Visual and anatomical outcomes of central serous chorioretinopathy patients presenting to a tertiary unit: a prospective analysis. 61
32529171 2020
111
Quantitative Assessment of Retinal Capillary Vessel Density and Foveal Avascular Zone Area in Central Serous Chorioretinopathy Using OCTA. 61
31962342 2020
112
Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy. 61
31863228 2020
113
CHANGES IN CHORIOCAPILLARIS, SATTLER, AND HALLER LAYER THICKNESSES IN CENTRAL SEROUS CHORIORETINOPATHY AFTER HALF-FLUENCE PHOTODYNAMIC THERAPY. 61
31985718 2020
114
Axial length as a basic anatomical predictor for morphological and clinical characteristics in acute central serous chorioretinopathy. 61
31969681 2020
115
CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
31815880 2019
116
Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. 61
31925308 2019
117
Bilateral diffuse uveal melanocytic proliferation secondary to thyroid carcinoma. 61
31755473 2019
118
A Novel Method for Detection and Progress Assessment of Visual Distortion Caused by Macular Disorder: A Central Serous Chorioretinopathy (CSR) Case Study. 61
31835894 2019
119
Choroidal binarization analysis: clinical application. 61
31140022 2019
120
Bilateral serous retinal detachment associated with subretinal fibrin-like material in a case of pregnancy-induced hypertension. 61
31788578 2019
121
Atypical Presentation of Choroidal Folds: Steroid-induced Central Serous Chorioretinopathy-like Maculopathy 61
31893595 2019
122
Relationship between heart failure and central serous chorioretinopathy: A cohort study in Taiwan. 61
31805017 2019
123
GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY. 61
30300269 2019
124
Pattern electroretinography in patients with unilateral acute central serous chorioretinopathy. 61
31822040 2019
125
Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy. 61
31833245 2019
126
Retinal pigment epithelium apertures as a late complication of longstanding serous pigment epithelium detachments in chronic central serous chorioretinopathy. 61
31267093 2019
127
The Correlation of Central Serous Chorioretinopathy and Subsequent Cardiovascular Diseases of Different Types: A Population-Based Cohort Study. 61
31847232 2019
128
Differential flow signal strength of choroidal neovascular membrane on optical coherence tomography angiography in central serous chorioretinopathy. 61
31806631 2019
129
Large choroidal excavation in pachychoroid disease: A case report. 61
31801362 2019
130
Longitudinal Analysis of the Choriocapillaris Using Optical Coherence Tomography Angiography Reveals Subretinal Fluid as a Substantial Confounder in Patients with Acute Central Serous Chorioretinopathy. 61
31654333 2019
131
Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy. 61
31844791 2019
132
Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy. 61
31877221 2019
133
Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. 61
31833247 2019
134
An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study. 61
31808315 2019
135
GENETIC RISK FACTORS IN SEVERE, NONSEVERE AND ACUTE PHENOTYPES OF CENTRAL SEROUS CHORIORETINOPATHY. 61
31815877 2019
136
Central serous chorioretinopathy: Towards an evidence-based treatment guideline. 61
31319157 2019
137
CHORIORETINAL FOLDS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY. 61
31764887 2019
138
PATTERNS OF CHORIOCAPILLARIS FLOW SIGNAL VOIDS IN CENTRAL SEROUS CHORIORETINOPATHY: An Optical Coherence Tomography Angiography Study. 61
30028410 2019
139
Short axial length and hyperopic refractive error are risk factors of central serous chorioretinopathy. 61
31780441 2019
140
IPSILATERAL BULLOUS EXUDATIVE RETINAL DETACHMENT ASSOCIATED WITH EXTRACORPOREAL MEMBRANE OXYGENATION. 61
31800505 2019
141
Predictive Genes for the Prognosis of Central Serous Chorioretinopathy. 61
31331787 2019
142
Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy. 61
30602447 2019
143
Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms. 61
31479654 2019
144
Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. 61
31784704 2019
145
THE ASSOCIATION BETWEEN CENTRAL SEROUS CHORIORETINOPATHY AND SLEEP APNEA: A Nationwide Population-Based Study. 61
31800457 2019
146
Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy. 61
31755972 2019
147
Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. 61
31267094 2019
148
Evaluation of choroidal hyperreflective dots in acute and chronic central serous chorioretinopathy. 61
31638047 2019
149
Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy. 61
31777490 2019
150
Evaluation of the choroidal features in pachychoroid spectrum diseases by optical coherence tomography and optical coherence tomography angiography. 61
31684767 2019
151
Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy. 61
31777516 2019
152
SEROUS MACULAR DETACHMENT IN BEST DISEASE: A Masquerade Syndrome. 61
31613838 2019
153
Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. 61
31401003 2019
154
Angiotensin II and aldosterone in retinal vasculopathy and inflammation. 61
31425690 2019
155
Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. 61
31367848 2019
156
[Nanosecond Laser Treatment in Chorioretinopathia Centralis Serosa without RPE Defects: A Retrospective Case Series]. 61
31600817 2019
157
FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy? 61
31584559 2019
158
Optical Coherence Tomography of Choroid in Common Neurological Diseases. 61
31471385 2019
159
Serous macular detachment in nanophthalmos: A manifestation of pachychoroid spectrum. 61
31384695 2019
160
Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset. 61
31500100 2019
161
Incident and recurrent cases of central serous chorioretinopathy, active component, U.S. Armed Forces, 2001-2018. 61
31557049 2019
162
Outcome of a fibrinous exudation in fibrinous central serous chorioretinopathy. The "Y" sign. 61
31151688 2019
163
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERISTICS OF POLYPOIDAL CHOROIDAL VASCULOPATHY SECONDARY TO CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
29965937 2019
164
[Does the micropulse laser have an effect on chronic CSC?] 61
30578429 2019
165
A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. 61
30710172 2019
166
Optical coherence tomography angiography to assess vascular remodeling of the choriocapillaris after low-fluence photodynamic therapy for chronic central serous chorioretinopathy. 61
31163282 2019
167
Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. 61
30951686 2019
168
COMBINING EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY WITH STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY AND BLOOD FLOW ANALYSIS FOR DETECTING CHOROIDAL NEOVASCULAR COMPLEXES IN PIGMENT EPITHELIAL DETACHMENTS. 61
29863533 2019
169
Test performance of optical coherence tomography angiography in detecting retinal diseases: a systematic review and meta-analysis. 61
30971815 2019
170
Association between visual function and the integrity of residual ellipsoid zone in resolved central serous chorioretinopathy. 61
31455795 2019
171
Multi-phase level set algorithm based on fully convolutional networks (FCN-MLS) for retinal layer segmentation in SD-OCT images with central serous chorioretinopathy (CSC). 61
31452990 2019
172
Central Serous Chorioretinopathy Following Intravitreal Dexamethasone Implant. 61
31389218 2019
173
The eye in dengue fever, a rarely appreciated aspect of dengue expanded syndrome: a case report. 61
31462315 2019
174
Concentric retinal pigment epithelium tear in central serous chorioretinopathy. 61
31332124 2019
175
Elevated Steroid Hormone Levels in Active Chronic Central Serous Chorioretinopathy. 61
31387112 2019
176
A patient misdiagnosed with central serous chorioretinopathy: A case report. 61
31531329 2019
177
Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). 61
31037488 2019
178
NGRID: A novel platform for detection and progress assessment of visual distortion caused by macular disorders. 61
31279165 2019
179
Spectrum of choroidal neovascularisation associated with dome-shaped macula. 61
30327318 2019
180
Expanding the OCT Spectrum of Acute Central Serous Chorioretinopathy: The Stalagmite-Stalactite Pattern. 61
31383396 2019
181
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. 61
30355720 2019
182
Multicolor imaging in central serous chorioretinopathy - a quantitative and qualitative comparison with fundus autofluorescence. 61
31409843 2019
183
Flat irregular pigment epithelium detachment in central serous chorioretinopathy: Correlation with choroidal neovascular membrane. 61
31332125 2019
184
Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy. 61
31443376 2019
185
Comment: Clinical profile of uveitis patients developing central serous chorioretinopathy - An experience at a tertiary eye care center in India. 61
31238489 2019
186
Double-branched and area-constraint fully convolutional networks for automated serous retinal detachment segmentation in SD-OCT images. 61
31200913 2019
187
RESOLUTION OF A SUBFOVEAL CHOROIDAL CAVERN AFTER HALF-DOSE PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. 61
31348118 2019
188
Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage. 61
31123815 2019
189
ASSESSMENT OF CENTRAL SEROUS CHORIORETINOPATHY DEPICTED ON COLOR FUNDUS PHOTOGRAPHS USING DEEP LEARNING. 61
31283737 2019
190
Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. 61
31345183 2019
191
Optical coherence tomography angiography versus fluorescein angiography in diagnosing choroidal neovascularization in chronic central serous chorioretinopathy. 61
31238419 2019
192
Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. 61
30824822 2019
193
INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
29554076 2019
194
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. 61
31126617 2019
195
Deep Learning Based Sub-Retinal Fluid Segmentation in Central Serous Chorioretinopathy Optical Coherence Tomography Scans. 61
31946057 2019
196
Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. 61
31256613 2019
197
Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy. 61
31274738 2019
198
Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy. 61
31037490 2019
199
TRANSIENT PARADOXICAL WORSENING OF VISION DUE TO GRAVITATIONAL SHIFT OF SUBRETINAL FLUID AFTER PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. 61
31313703 2019
200
Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients. 61
30002072 2019
201
Sensitivity and Specificity of Potential Diagnostic Features Detected Using Fundus Photography, Optical Coherence Tomography, and Fluorescein Angiography for Polypoidal Choroidal Vasculopathy. 61
30973593 2019
202
PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors. 61
29517581 2019
203
Recent Advances of Computerized Graphical Methods for the Detection and Progress Assessment of Visual Distortion Caused by Macular Disorders. 61
31735826 2019
204
Optical coherence tomography angiography image quality assessment at varying retinal expertise levels. 61
31317094 2019
205
Discrepancy in current central serous chorioretinopathy classification. 61
30002069 2019
206
Clinical characteristics of pachydrusen in central serous chorioretinopathy. 61
30852634 2019
207
Peripheral retinal avascularity and capillary leakage in central serous chorioretinopathy. 61
31317104 2019
208
Optical Coherence Tomography Angiography for Diagnosis of Choroidal Neovascularization in Chronic Central Serous Chorioretinopathy after Photodynamic Therapy. 61
31227727 2019
209
Investigating the Hypothesis of Stress System Dysregulation as a Risk Factor for Central Serous Chorioretinopathy: A Literature Mini-Review. 61
30624085 2019
210
Rates of Serious Complications Estimated by the ACS-NSQIP Surgical Risk Calculator in Predicting Oncologic Outcomes of Patients Treated with Pancreaticoduodenectomy for Pancreatic Head Cancer. 61
30465189 2019
211
Generation of an E. coli platform strain for improved sucrose utilization using adaptive laboratory evolution. 61
31255177 2019
212
Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. 61
30378259 2019
213
Hair cortisol concentration in patients with active central serous chorioretinopathy is elevated - a pilot study. 61
30565878 2019
214
CORRELATIONS BETWEEN CHANGES IN PHOTORECEPTOR LAYER AND OTHER CLINICAL CHARACTERISTICS IN CENTRAL SEROUS CHORIORETINOPATHY. 61
29401176 2019
215
Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy. 61
29916122 2019
216
Double Gutter in Central Serous Chorioretinopathy. 61
31070684 2019
217
Intranasal Corticosteroids and Central Serous Chorioretinopathy: A Report and Review of the Literature. 61
31049263 2019
218
High-Resolution In Vivo Fundus Angiography using a Nonadaptive Optics Imaging System. 61
31293809 2019
219
CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. 61
29346241 2019
220
Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. 61
30610228 2019
221
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. 61
30616898 2019
222
Predictive Factors of Response to Mineralocorticoid Receptor Antagonist in Nonresolving Central Serous Chorioretinopathy. 61
30683307 2019
223
Optical Coherence Tomography Angiography Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy. 61
30871715 2019
224
Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy. 61
30515936 2019
225
Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. 61
30617579 2019
226
A two-year study of diffused retinal pigment epitheliopathy treated with half-dose photodynamic therapy guided by simultaneous angiography and optical coherence tomography. 61
30531992 2019
227
Bilateral Multiple Serous Retinal Detachments Following Bone Marrow Transplantation. 61
31114660 2019
228
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy. 61
30659849 2019
229
Exome sequencing in patients with chronic central serous chorioretinopathy. 61
31036833 2019
230
Exome sequencing in families with chronic central serous chorioretinopathy. 61
30724488 2019
231
A Backward Glance at Chronic Central Serous Chorioretinopathy. 61
30910041 2019
232
Evaluation of Choroidal Layer Thickness in Central Serous Chorioretinopathy. 61
31114653 2019
233
Anatomical and Functional Changes of the Retina and the Choroid after Resolved Chronic CSCR. 61
30959979 2019
234
Re: van Dijk et al.: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial (Ophthalmology. 2018;125:1547-1555). 61
30910047 2019
235
[Central serous chorioretinopathy secondary to Helicobacter pylori: To treat or not to treat, that is the question]. 61
30552035 2019
236
Clinical Application of Fluorescein Angiography-Free Navigated Focal Laser Photocoagulation in Central Serous Chorioretinopathy. 61
30998255 2019
237
Optical Coherence Tomography Angiography Compared with Indocyanine Green Angiography in Central Serous Chorioretinopathy. 61
30992527 2019
238
Optical Coherence Tomography Angiography Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy. 61
30935474 2019
239
Choroidal Neovascularisation Complicating Chronic Central Serous Chorioretinopathy: The Discovery Rate on Multimodal Imaging. 61
30999331 2019
240
Dome shaped maculopathy with tilted disc misdiagnosed as central serous chorioretinopathy. 61
31036744 2019
241
OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis. 61
30617944 2019
242
Macular telangiectasia type II with pachychoroid spectrum of macular disorders. 61
29676172 2019
243
Increased risk of central serous chorioretinopathy following end-stage renal disease: A nationwide population-based study. 61
30882685 2019
244
Serous Retinal Detachment Causes a Transient Reduction on Spectral Domain OCT Estimates of Ganglion Cell Layer Thickness. 61
30741788 2019
245
The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy. 61
30922273 2019
246
Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. 61
30850639 2019
247
Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report. 61
30849939 2019
248
Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy 61
30829023 2019
249
Effect of Serous Retinal Detachment on the Measurement of Axial Length in Central Serous Chorioretinopathy. 61
30746913 2019
250
Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India. 61
30672479 2019
251
FAMILIAL CENTRAL SEROUS CHORIORETINOPATHY. 61
29190234 2019
252
Central serous chorioretinopathy in elderly subjects: angiographic and tomographic characteristics. 61
30564905 2019
253
[Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists]. 61
30255262 2019
254
Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment 61
30829024 2019
255
Statement of the Professional Association of German Ophthalmologists (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018. 61
30411167 2019
256
Detection of secondary choroidal neovascularization in chronic central serous chorioretinopathy by swept source-optical coherence tomography angiography. 61
30284407 2019
257
Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. 61
30194380 2019
258
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. 61
30308202 2019
259
Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. 61
31014765 2019
260
Optical coherence tomography angiography findings in fellow eyes of choroidal neovascularisation associated with central serous chorioretinopathy. 61
30798261 2019
261
Quetiapine associated Central Serous Chorioretinopathy: Implicit role of serotonin and dopamine pathways. 61
30672500 2019
262
Central serous chorioretinopathy with and without steroids: A multicenter survey. 61
30818363 2019
263
Choroidal neovascularization following argon laser photocoagulation for central serous chorioretinopathy. 61
31535710 2019
264
The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy. 61
31205784 2019
265
Treatment of central serous chorioretinopathy with topical NSAIDs. 61
31616132 2019
266
Masqueraders of central serous chorioretinopathy. 61
30243734 2019
267
Central Serous Chorioretinopathy: Pathogenesis and Management. 61
31819359 2019
268
Association between Central Serous Chorioretinopathy and Risk of Depression: A Population-Based Cohort Study. 61
31191993 2019
269
Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy. 61
31485346 2019
270
Can Hypothyroidism Cause Acute Central Serous Chorioretinopathy? 61
31646925 2019
271
Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake. 61
30175623 2019
272
Bilateral serous retinal detachment accompanied by a rare intraretinal fluid configuration in preeclampsia and PRES Syndrome. 61
31198902 2019
273
Acute vision loss in multiple sclerosis: Optic neuritis or central serous chorioretinopathy? 61
30384200 2019
274
Ranibizumab for the treatment of choroidal neovascularization due to cause other than age related macular degeneration. 61
31779462 2019
275
An unusual case of multifocal central serous chorioretinopathy with low serum cortisol managed using eplerenone. 61
30574936 2019
276
Central serous chorioretinopathy following ingestion of sildenafil citrate. 61
31372081 2019
277
The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy. 61
31309849 2019
278
Combined Parafoveal Telangiectasia, Multifocal Central Serous Chorioretinopathy, and Choroidal Hemangioma. 61
31114127 2019
279
Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. 61
31872073 2019
280
Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide. 61
30774304 2019
281
Optical Coherence Tomography Angiography Findings in Chronic Central Serous Chorioretinopathy After Photodynamic Therapy. 61
30640392 2019
282
Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study. 61
31516734 2019
283
Application of the Balloon Snake in the Volume Measurement of Subretinal Fluid in Central Serous Chorioretinopathy. 61
31288617 2019
284
Choroidal Changes at the Leakage Site in Acute Central Serous Chorioretinopathy. 61
31257974 2019
285
Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. 61
30110697 2019
286
Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. 61
30058731 2019
287
Chorioretinal response to intravitreal aflibercept injection in acute central serous chorioretinopathy. 61
31850170 2019